Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238817 | 0.96 | MAOB (0.72) | MAOBMAOA | |
| SCHEMBL29545160 | 0.96 | MAOB (0.72) | MAOBMAOA | |
| SCHEMBL6588324 | 0.94 | MAOB (0.70) | MAOBMAOA | |
| SCHEMBL6585582 | 0.94 | MAOB (0.67) | MAOBMAOA | |
| SCHEMBL2842062 | 0.92 | MAOB (0.80) | MAOBMAOA | |
| SCHEMBL1038939 | 0.89 | MAOB (0.62) | MAOBMAOA | |
| SCHEMBL426467 | 0.88 | MAOB (0.70) | MAOBMAOA | |
| SCHEMBL18892577 | 0.88 | MAOB (0.76) | MAOBMAOA | |
| SCHEMBL1207052 | 0.88 | MAOB (0.66) | MAOBMAOA | |
| SCHEMBL6001124 | 0.87 | MAOB (0.62) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-RE48059-E1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-20190117648-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20170368060-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9839637-B1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-12 | — | — | US | disclosed |
| US-20170231983-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170000786-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-01-05 | — | — | US | disclosed |
| CN-101607959-A | The dihydroquinoline ketone derivatives, its preparation method and be the pharmaceutical composition of activeconstituents with this compound | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-12-23 | — | — | CN | disclosed |
| EP-1869025-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006112464-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
| EP-0957100-B1 | DIAMINE DERIVATIVES AND PHARMACEUTICAL CONTAINING THE SAME | KOWA CO (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-0957100-A1 | DIAMINE DERIVATIVES AND PHARMACEUTICAL CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 1999-11-17 | — | — | EP | disclosed |
| US-4914094-A | CARBOSTYRIC OR BENZOXAZINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| US-4824840-A | ANTIHISTAMINES, NERVOUS SYSTEM CONTROLLERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-25 | — | — | US | disclosed |
| US-4734416-A | ANTIHISTAMINES, CENTRAL NERVOUS SYSTEM CONTROLLING ACTION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| EP-0226441-A2 | Preparation of pharmaceutical compositions for the treatment of hypoxia | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-06-24 | — | — | EP | disclosed |
| US-4482560-A | Carbostyril derivatives, and antihistaminic agents containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368060-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885 |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885 |
| US-20190117648-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885 |
| US-20170000786-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885 |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885 |
| US-20170231983-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885 |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885 |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.